161 / 172
161
133.Verstappen SM, Jacobs JW, Bijlsma JW, Heurkens AH, van
Booma-Frankfort C, Borg EJ, et al. Five-year followup of
rheumatoid arthritis patients after early treatment with disease
modifying antirheumatic drugs versus treatment according to
the pyramid approach in the first year. Arthritis Rheum
2003;48:1797-807.
134.Matsumoto AK, Melian A, Mandel DR, McIlwain HH,
Borenstein D, Zhao PL, et al. A randomized, controlled, clinical
trial of etoricoxib in the treatment of rheumatoid arthritis. J
Rheumatol 2002;29:1623-30.
135.Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T,
Melian A, et al. A multinational randomized, controlled,
clinical trial of etoricoxib in the treatment of rheumatoid
arthritis. BMC Fam Pract 2002;3:10.
136.Choy EH, Scott DL, Kingsley GH, Williams P, Wojtulewski
J, Papasavvas G, et al. Treating rheumatoid arthritis early with
disease modifying drugs reduces joint damage: a randomised
double blind trial of sulphasalazine vs diclofenac sodium. Clin
Exp Rheumatol 2002;20:351-8.
137.Furst DE, Kolba KS, Fleischmann R, Silverfield J,
Greenwald M, Roth S, et al. Dose response and safety study of
meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12
week multicenter, double blind, dose response study versus
placebo and diclofenac. J Rheumatol 2002;29:436-46.
138.Zhao SZ, Fiechtner JI, Tindall EA, Dedhiya SD, Zhao WW,
Osterhaus JT, et al. Evaluation of health-related quality of life
of rheumatoid arthritis patients treated with celecoxib.
Arthritis Care Res 2000;13:112-21.
139.Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE,
Hubbard RC, et al. Anti-inflammatory and upper
gastrointestinal effects of celecoxib in rheumatoid arthritis: a
randomized controlled trial. JAMA 1999;282:1921-8.
140.Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R,
Stead H, et al. Celecoxib versus diclofenac in long-term